Edgewise Therapeutics, Inc. SEC filings EWTX

Edgewise Therapeutics, Inc. has 422 filings in SEC EDGAR's recent list, going back to Sep 26, 2019. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.

Edgewise Therapeutics, Inc. SEC filings
Form Description Filed Period
DEFA14A Additional proxy material Apr 23, 2026 —
DEF 14A Proxy statement Apr 23, 2026 Jun 4, 2026
DEFA14A Additional proxy material May 14, 2025 —
DEFA14A Additional proxy material Apr 29, 2025 —
DEF 14A Proxy statement Apr 29, 2025 Jun 13, 2025
DEFA14A Additional proxy material May 7, 2024 —
DEFA14A Additional proxy material Apr 26, 2024 —
DEF 14A Proxy statement Apr 26, 2024 Jun 7, 2024
PRE 14A Preliminary proxy statement Apr 15, 2024 Jun 7, 2024
DEFA14A Additional proxy material Apr 28, 2023 —
DEF 14A Proxy statement Apr 28, 2023 Jun 9, 2023
DEFA14A Additional proxy material May 2, 2022 —
DEF 14A Proxy statement May 2, 2022 Jun 23, 2022

Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
EWTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boulder, CO
SEC filer status
Large accelerated filer
SEC CIK
1710072

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.